Knight C, Marbaix S, Annemans L, Prignot J, Bowrin K
HERON Evidence Development Ltd., Luton, UK.
Acta Clin Belg. 2012 Nov-Dec;67(6):416-22. doi: 10.2143/ACB.67.6.2062706.
To evaluate the cost-effectiveness of an extended (12+12 weeks) course of varenicline plus brief counselling compared with the currently reimbursed smoking cessation interventions (in combination with brief counselling) in Belgium, from a public payer perspective.
The previously published version of the BENESCO model which included the extended course of varenicline was updated with recent publically available demographic and cost data from Belgium.
The extended course of varenicline plus brief counselling has an incremental cost per quality adjusted life year gained of 1101€ compared with a nonextended 12-week course of varenicline (plus brief counselling). The extended course of varenicline dominates all other comparators in this analysis.
The extended course of varenicline (12 weeks followed by 12 weeks maintenance therapy in successful quitters) plus brief counselling is a highly cost-effective alternative to a non-extended (12 weeks only) course of varenicline plus brief counselling. This strategy dominates the other alternative smoking cessation interventions currently reimbursed in Belgium.
从公共支付方的角度，评估在比利时，与目前已获报销的戒烟干预措施（结合简短咨询）相比，伐尼克兰延长疗程（12 + 12周）加简短咨询的成本效益。
使用比利时近期公开的人口统计学和成本数据，对之前发表的包含伐尼克兰延长疗程的BENESCO模型进行更新。
与未延长的12周伐尼克兰疗程（加简短咨询）相比，伐尼克兰延长疗程加简短咨询每获得一个质量调整生命年的增量成本为1101欧元。在该分析中，伐尼克兰延长疗程优于所有其他对照措施。
伐尼克兰延长疗程（成功戒烟者先进行12周治疗，随后进行12周维持治疗）加简短咨询是未延长的（仅12周）伐尼克兰疗程加简短咨询的一种高成本效益替代方案。该策略优于比利时目前已获报销的其他戒烟干预措施。
